Poster Abstracts
P001 Two years experience with doravirine
P002 Performance of dolutegravir based two drug regimens (DTG-2DR) in a large real-world cohort of people with HIV
P003 Approaches to Optimise Recruitment of Historically Underrepresented Black and Hispanic/LatinX MSM, Transgender, and Gender Non-binary Individuals into the Lenacapavir for PrEP (PURPOSE 2) Trial
P004 Lenacapavir as part of a combination regimen in treatment naïve people living with HIV: Week 54 results
P005 In Vitro Forgiveness of Oral and Long-Acting INSTI-Containing Regimens at Drug Concentrations Simulating Variable Adherence
P006 Long acting lenacapavir in people with multi-drug resistant HIV-1: Week 52 results
P007 History of drug resistance mutations and virological outcomes for two-drug regimens: data from COMBINE-2
P008 Top Practices for Implementing Cabotegravir (CAB) and Rilpivirine (RPV) Long-acting (LA) in European Clinics
P009 Two cases of NNRTI resistance developed through planned interruption to long-acting injectable (LAI) Cabotegravir/Rilpivirine to facilitate conception
P010 Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for the treatment of people living with HIV (PLWH): 12-month (12M) effectiveness, persistence, and safety in a multi-country cohort study
P011 B/F/TAF five-year outcomes in treatment-naïve adults
P012 Real life experience of Doravirine in a large multi-centre HIV service
P013 Real world data of people living with HIV-2: experience of 7 London clinics
P014 Real world data of doravirine usage: efficacy and safety outcomes in a large urban HIV service
P015 The safety and efficacy of the use of Biktarvy (bictegravir, emtricitabine and tenofovir alafenamide) with boosted Darunavir in clinical practice
P016 Antiretroviral regimen simplification for individuals receiving maraviroc
P017 Impact of treatment adherence on efficacy of dolutegravir + lamivudine and dolutegravir + tenofovir disoproxil fumarate/emtricitabine: pooled week 144 analysis of the GEMINI-1 and GEMINI-2 clinical studies
P018 Three versus four drug regimens for people with high and very high viral loads
P019 Dolutegravir/Lamivudine efficacy outcomes in people living with HIV with or without resistance results: 48-week pooled analysis
P020 Efficacy and safety outcomes by BMI category over 48 weeks in phase 3/3b cabotegravir and rilpivirine long-acting trials
P021 Multi-tablet, single-tablet, or long-acting antiretroviral treatment for HIV: a cross sectional study examining patient preference in two outpatient settings in the United States and Spain
P022 Anti-retroviral therapy modification in an acute setting
P023 Effectiveness and tolerability of the 2-drug regimen dolutegravir plus lamivudine in people with HIV-1: a systematic literature review of real-world evidence from clinical practice
P024 Treatment-emergent resistance to bictegravir with minimal risk factors
P025 Evolution of Natural Killer (NK) cell responses during acute HIV-1 infection with distinct viral subtypes
P026 People living with HIV have higher frequencies of circulating endothelial colony-forming cells: steps towards patient-specific models to evaluate cardiovascular risk
P027 Towards a prophylactic HIV vaccine: fine needle aspiration reveals cellular features of human lymph nodes compared with blood in the EAVI2020_01 study
P028 Effective CD4 count restoration linked to SARS-CoV-2 seroconversion following BNT162b2 mRNA SARS-CoV-2 vaccine in people living with HIV (PLWH) – a case report
P029 Increasing HPV vaccination uptake in PLWHIV: the need to improve both clinician training and patient health promotion
P030 Long-term Outcomes of Participants on F/TAF for Pre-Exposure Prophylaxis: Results for 144 Weeks of Follow-Up in the DISCOVER Trial
P031 ‘Health tourism’ in the UK: challenging negative beliefs affecting the healthcare rights of migrants living with HIV
P032 Terrence Higgins Trust and NHS Greater Glasgow & Clyde HIV testing campaign
P033 Optimising PrEP delivery - where and how people want to get PrEP. Findings from the 2020 PrEP User Survey
P034 Outcomes of a national complex HIV pre-exposure prophylaxis (PrEP) multi-disciplinary meeting
P035 Barriers of PrEP use among people who recently acquired HIV: qualitative study. Findings from the SHARE (Surveillance of HIV Acquired Recently) initiative
P036 Psycho-social factors affecting treatment compliance: The need for a patient-centred approach
P037 An audit of management of HIV in pregnancy at an ISHS, compared to BHIVA Guidelines for the management of HIV in pregnancy and postpartum 2020
P038 Use of video observed therapy as an adherence support for pregnant women living with HIV: A case report
P039 Confinement : Women, HIV And Pregnancy During The Covid-19 Pandemic In The UK
P040 Exploring how women and birthing parents living with HIV make decisions about infant-feeding in the UK
P041 Trends in maternal characteristics and pregnancy outcomes among women living with HIV in the UK: 2014-19
P042 Pregnancy outcomes of women conceiving on ART at a London HIV clinic 2015-2020
P043 Withdrawn
P044 Cervical screening and HPV testing in young women living with perinatally acquired HIV: An interim assessment of the SHiP study
P045 Lipid disorders in HIV patients and impact on raised HDL cholesterol level
P046 Prognostic relevance of lymphocyte-CRP-ratio and CRP-albumin-ratio as markers of inflammation in hospitalised adults with HIV
P047 Assessing health-related quality of life in people with HIV and cognitive issues
P048 Inflammatory conditions necessitating immunosuppression in a cohort of young adults with perinatally acquired HIV: A case series
P049 Impact of antiretroviral (ARV) and sleep hygiene intervention on sleep disturbance in people living with HIV (PLWH)
P050 Metabolic health of young adults with perinatally acquired HIV – an unknown need?
P051 Spotlight on British South Asians living with HIV
P052 Smoking prevalence in people living with HIV in Cheshire and Merseyside is high, and supporting quitting could eradicate lifelong harms for over one quarter of the cohort
P053 Impact on inflammatory and atherogenesis biomarkers with the 2-drug regimen dolutegravir plus lamivudine in treatment-experienced people with HIV-1: a systematic literature review
P054 Patient-reported outcomes after switching to a 2-drug regimen of fixed-dose combination dolutegravir/lamivudine: 48-week results from the SALSA study
P055 Weight change in youth on tenofovir alafenamide (TAF)
P056 Associations between inflammatory profiles and cardiovascular disease risk among people living with HIV
P057 The assessment of hepatic fibrosis and steatosis using transient elastography in youth with perinatal HIV
P058 SARS-CoV2 vaccination acceptance in people with HIV
P059 Hyper-eosinophilic syndrome with neurological and gastrointestinal involvement in a patient living with HIV
P060 Re-evaluation of annual cytology using HPV self-sampling to upgrade prevention (REACH UP): a feasibility study in women living with HIV in the UK
P061 Physical inactivity and associated health factors among patients attending an urban UK HIV and sexual health clinic: a secondary analysis of a clinic-based cross-sectional survey
P062 SARS-CoV-2 antibody seroprevalence in a large HIV clinic cohort
P063 Management of active tuberculosis in people living with HIV in a tertiary centre
P064 COVID infection and vaccination in a semi-rural HIV cohort
P065 Unexpected HIV Viral load rises in a COVID pandemic
P066 Missed opportunities for diagnosing HIV in primary care
P067 Offering mass HIV blood testing to Primary Care patients via (MJog) Text Message: What we learnt and did it work?
P068 Introducing routine HIV testing to a gastroenterology ward: a junior doctor-led project
P069 A re-audit of late diagnosed HIV positive individuals in 2016 and 2019 in Greater Manchester
P070 Improving testing for HIV in patients with community acquired pneumonia in Bradford Teaching Hospitals
P071 The use of routine diagnostic sequencing data to determine the molecular epidemiology and transmission dynamics of HIV-1 in Newcastle-upon-Tyne
P072 Improving blood-borne pathogen (BBP) testing on an adult inpatient mental health ward
P073 Measuring progress towards ending HIV transmission in England in the COVID-19 pandemic era
P074 Characterising late presentation amongst people living with HIV in England who were previously diagnosed abroad
P075 A whole systems approach to improving HIV testing in UK General Practice
P076 HIV Testing in Indicator Conditions: Knowledge and Confidence in Primary Care
P077 Service evaluation of the current standard of care for elite controllers, viral controllers and long term non-progressors in an age of antiretroviral therapy (ART) for all
P078 Regimens and outcomes for people with HIV and known hepatitis B core antibody positivity
P079 Networking for HIV/AIDS prevention: impact of social media promotion on widening access and uptake of HIV testing
P080 Real-world patient experience of long-acting injectable antiretroviral therapy (LAI-ART): The voice of young adults with perinatally acquired HIV (YAPAH)
P081 Screening positive for depression is associated with poor self-reported adherence to antiretroviral therapy among people living with HIV attending a sexual health and HIV clinic in the UK
P082 Life Really Changed: Challenging people’s perceptions of what it’s like to live with HIV
P083 Developing a model of dating for young adult women living with HIV
P084 Wellbeing of Black African women over 50 living with HIV
P085 Medicine-related burden in people living with HIV
P086 Stigma related to HIV pre-exposure prophylaxis use among men who have sex with men in Wales: a mixed methods study
P087 Patient-reported outcome measures at 12 months in a real-world cohort of people living with HIV receiving bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Europe, Canada, and Israel
P088 Ageing with HIV and co-morbidities: Exploring the social constructs of ageing and NCDs in the context of HIV in Zambia
P089 “The stigma being with HIV and double stigma being black”: experiences and needs of racially minoritised people living with HIV
P090 Understanding the perceived therapeutic need and value associated with novel long-acting antiretroviral regimens among people living with HIV in 12 European countries
P091 “You are kind of left out there in a field on your own, and you have to figure it out yourself”: responding to the needs of women ageing with HIV
P092 Characteristics and outcomes of domestic abuse (DA) in people living with HIV (PLWH)
P093 A review of the management of people living with HIV in long-term residential/nursing care in a greater London cohort
P094 Improving U=U discussions with people living with HIV: an audit of practice in an infectious diseases clinic
P095 The prevalence and impact of severe hot flushes among women aged 45-60 living with HIV in England
P096 Interest in, and feasibility of, a genital Herpes Simplex Virus Type-2 infection vaccine study in a cohort of people living with HIV
P097 Implementing a menopausal service for women living with HIV (WLWH)
P098 Preferences for the management of sexually transmitted infections in the South African health system: A discrete choice experiment
P099 Vaccine administration and monitoring in a regional HIV centre: a service evaluation
P100 Improving the quality of care for people living with HIV (PLWH) in Primary Care
P101 HIV care during Covid: Learning from patients’ experiences
P102 Reduced monitoring in a stable patient pathway: Patients’ perspective and co-design
P103 Have HIV inpatient and outpatient care become disconnected?
P104 'Zero HIV’: a primary care population-based project to increase HIV diagnosis and improve engagement of patients living with HIV
P105 A quality improvement project to increase the uptake of Human Papilloma Virus vaccine for HIV+ women aged <40
P106 Achieving high levels of engagement among UK primary and secondary healthcare professionals using a World AIDS Day digital media, augmented reality, and email education campaign
P107 Patient and clinician experience of video and telephone appointments (VATA) vs face-to-face appointments (FTFA) in a large urban HIV service
P108 The experiences of individuals living with HIV in Ireland attending for out-patient physiotherapy
P109 A simulation modelling evaluating the impact of mobile health interventions on HIV/AIDS service delivery
P110 Success of peer mentoring in supporting patients to improve virological control: a collaborative project supported by the Fast Track Cities (FTC) initiative
P111 From engagement to co-production: London’s Improvement Collaborative as a model for partnership between clinical and community-based services
P112 Intervention to support retention in care in individuals at risk of disengagement during the COVID 19 pandemic
P113 Challenging Glasgow’s HIV outbreak through support, prevention and care: an evaluation of Waverley Care’s HIV Street Support Project
P114 General population understanding and self-reported attitudes towards people living with HIV
P115 Improving access to hepatitis C treatment in people living with HIV
P116 Development of a multi-professional approach for holistic frailty assessments in the HIV population to improve patient care
P117 Patient and staff perspective on screening for domestic abuse (DA) in people living with HIV (PLWH) during a COVID pandemic
P118 The ePrEP Clinic: developing a clinical consultation for online PrEP provision
P119 Quality improvement project: A review of patients with historic Didanosine (ddI) exposure to ensure assessment for liver toxicity
P120 Identifying factors associated with low COVID-19 vaccination uptake in a diverse London HIV cohort
